繁體
  • 简体中文
  • 繁體中文

熱門資訊> 正文

Theratechnologies Reports on its Annual Meeting of Shareholders

2025-05-29 18:00

MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting.

Shareholders proceeded to elect the below candidates to the Company’s Board of Directors for a one-year term, appointed KPMG LLP as the Company’s auditors for the current fiscal year and approved the adoption of an omnibus long-term incentive plan for the benefits of the directors, executive officers and employees of the Company and those of its subsidiaries.

All candidates proposed for the position of director were elected in the following proportion:

  FOR % FOR ABSTENTION % ABSTENTION
Joseph Arena 20,473,944 84.03% 3,890,222 15.97%
Frank Holler 19,089,786 78.35% 5,274,380 21.65%
Paul Lévesque 19,027,772 78.10% 5,336,394 21.90%
Andrew Molson 19,066,145 78.25% 5,298,021 21.75%
Dawn Svoronos 18,998,230 77.98% 5,365,936 22.02%
Elina Tea 19,163,502 78.65% 5,200,664 21.35%
Dale Weil 19,005,768 78.01% 5,358,398 21.99%
Jordan Zwick 19,618,725 80.52% 4,745,441 19.48%
         

About Theratechnologies

Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Follow Theratechnologies on Linkedin and X (formerly Twitter).

Contacts:

Investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
pdubuc@theratech.com
438-315-6608

Media inquiries:
Julie Schneiderman
Senior Director, Communications & Corporate Affairs
communications@theratech.com
514-336-7800


風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。